Reviewed evidence dossier / RT-01
Retatrutide evidence:
phase 2, without shortcuts.
Published human studies report body-weight, glycemic, liver-fat, and tolerability findings in defined phase 2 populations. This dossier separates those direct observations from receptor rationale, broader class evidence, and claims the cited trials did not test.
Protocol-defined human findings.
The cited trials directly support only the populations, materials, comparators, endpoints, timeframes, and tolerability observations they report.
Catalog equivalence or whole-body benefit.
It does not establish the identity or quality of a separate vial, individual outcomes, unstudied organ effects, long-term safety, approval, or a suggested use.
What kind of answer can this dossier provide?
Retatrutide is an investigational triple receptor agonist with published randomized phase 2 evidence. The human record summarized here is strongest for the specific metabolic and tolerability endpoints measured in those trials. A receptor target, a class-wide observation, or a phase 3 registry entry is not interchangeable with a published Retatrutide outcome.
Three receptor targets are a research rationale—not a universal conclusion.
Retatrutide is described in its clinical program as an agonist at GIP, GLP-1, and glucagon receptors. That profile motivates research across metabolic systems. It does not prove an outcome in every tissue where a receptor or downstream pathway is present.
A publication about a study material does not verify the sequence, chemical form, concentration, purity, stability, or biological equivalence of a separate commercial research material.
Finding, model, limitation, source.
PHASE 2
Obesity trial: body weight and metabolic measures
In a 338-participant randomized trial, mean body-weight change at 48 weeks reached −24.2% in one study group versus −2.1% with placebo. Waist circumference, selected cardiometabolic measures, and tolerability were also recorded.
Limit: This is a group-level result within one protocol; it is not an individual prediction, use recommendation, or long-term outcome.
PHASE 2
Type 2 diabetes trial: glycemic endpoints
A separate randomized trial in adults with type 2 diabetes reported changes in HbA1c, fasting glucose, body weight, and tolerability.
Limit: The study does not establish beta-cell growth, regeneration, disease modification, or outcomes in populations outside its protocol.
PHASE 2A
MASLD substudy: MRI-measured liver fat
In a 98-participant substudy, mean relative liver-fat reduction at 24 weeks ranged from 42.9% to 82.4% across study groups, compared with a 0.3% increase with placebo.
Limit: MRI-measured liver fat does not establish reversal of fibrosis, long-term liver outcomes, or an approved liver-disease use.
TOLERABILITY
Adverse-event reporting belongs beside outcomes
Gastrointestinal events were the most commonly reported adverse events and were generally mild to moderate. The obesity trial also reported dose-dependent heart-rate increases that peaked during the study and later declined.
Limit: Phase 2 trials cannot resolve every uncommon or long-term risk.
MECHANISM
GLP-1 class evidence is not direct Retatrutide evidence
A 2025 review discusses intestinal-barrier and inflammatory hypotheses for the broader GLP-1 receptor agonist class, drawing on preclinical and early retrospective evidence.
Limit: This cannot be relabeled as prospective Retatrutide evidence.
Questions the cited record does not answer.
Phase 2 findings do not establish uncommon harms, durability, or long-term clinical outcomes.
The cited studies do not establish neuroprotection, memory enhancement, plaque reduction, kidney-disease progression, lung function, or immune-cell reprogramming.
A trial record, development phase, or published paper is not approval. Current status must be checked in live regulator databases.
The cited record does not establish identity, purity, safety, efficacy, approval, or intended use for PSC or another supplier’s material.
What the cited record can—and cannot—answer.
What is Retatrutide?
Retatrutide is a research-stage triple receptor agonist targeting GLP-1, GIP, and glucagon receptors. That receptor profile supplies a reason to investigate several systems; it does not establish an outcome wherever those receptors or related pathways are present.
What human evidence is included in this dossier?
A 338-participant phase 2 obesity trial, a phase 2 trial in adults with type 2 diabetes, and a 98-participant phase 2A MASLD substudy. The studies examined different populations and endpoints and should be read separately.
What did the cited studies measure?
The obesity study recorded body weight, waist circumference, selected cardiometabolic measures, and tolerability. The diabetes study recorded HbA1c, fasting glucose, body weight, and tolerability. The MASLD substudy used MRI to measure liver fat.
Did the liver-fat substudy establish changes in fibrosis or long-term liver outcomes?
No. The cited substudy measured liver fat by MRI. It did not establish reversal of fibrosis or long-term liver outcomes.
Do these studies establish claims about the brain, kidneys, lungs, immune system, or cardiovascular system?
No. The cited phase 2 records do not establish neuroprotection, memory enhancement, plaque reduction, slower kidney-disease progression, improved lung function, or immune-cell reprogramming.
Does this dossier evaluate any PSC catalog vial?
No. Published evidence for a study material does not establish the identity, equivalence, purity, safety, efficacy, approval, or intended use of a separate catalog material.
Open the studies, not the social summary.
- Jastreboff et al. · New England Journal of Medicine · 2023Randomized, double-blind, placebo-controlled phase 2 obesity trial · NCT04881760 · DOI 10.1056/NEJMoa2301972.PubMed 37366315 ↗
- Rosenstock et al. · The Lancet · 2023Randomized, double-blind, placebo- and active-controlled phase 2 trial in adults with type 2 diabetes · NCT04867785.PubMed 37385280 ↗
- Sanyal et al. · Nature Medicine · 2024Phase 2a MASLD substudy with MRI-measured liver-fat endpoint.PubMed 38858523 ↗
- Colwill et al. · Journal of Crohn’s and Colitis · 2025Class-wide review used only for GLP-1 receptor agonist hypotheses; not direct Retatrutide efficacy evidence.Publisher record ↗
Versioned, not silently rewritten.
Version 1.0 published. Extracted the source-led material from the PSC research hub, added claim-linked FAQs and explicit catalog-equivalence boundaries, and verified PMID/NCT identifiers.
A substantive correction records the date, changed statement, reason, and supporting source. Send a precise citation or correction request through the PSC policies and contact page.